Biotech company Biogen (NASDAQ:BIIB) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 7.3% year on year to ...

Biogen’s second quarter delivered results that exceeded Wall Street’s revenue and profit expectations, a performance that was ...

The First Trust Health Care AlphaDEX ETF (FXH) was launched on 05/08/2007, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market.What ...

Anavex faces dilution risk from its $150M ATM facility, high cash burn, and lack of revenue. Click here to see why AVXL stock ...

Cambridge-based Biogen is looking to the growth of its Alzheimer’s drug Leqembi to offset the decline of its multiple ...

In the EMPEROR trial, children with a confirmed variant in the SCN1A gene not associated with gain-of-function mutations will receive zorevunersen or a placebo.